On October 13, Moderna, Inc. fell 3.99% in Pre-Market Trading, trading near $205.283 per share, with turnover of $27.3994 million.
The move followed continued profit-taking after the company’s October 9 inclusion in the Nasdaq-100 had previously driven a sharp rally, while the passive-fund support effect appeared to be gradually absorbed.
Recent developments showed Moderna, Inc. had surged after joining the Nasdaq-100 and as commercialization expectations for personalized cancer vaccine intismeran autogene strengthened. However, the latest trading sessions already showed a visible reversal, including a 6.07% pullback in the prior session after an intraday decline of 3.28%, indicating short-term funds were locking in gains even as bullish options activity and oncology vaccine optimism had lifted sentiment earlier.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)